- Home
- BH vs AQST Comparison
BH vs AQST Comparison
Compare BH & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BH
- AQST
- Stock Information
- Founded
- BH 1934
- AQST 2004
- Country
- BH United States
- AQST United States
- Employees
- BH N/A
- AQST N/A
- Industry
- BH Restaurants
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- BH Consumer Discretionary
- AQST Health Care
- Exchange
- BH Nasdaq
- AQST Nasdaq
- Market Cap
- BH 561.5M
- AQST 502.6M
- IPO Year
- BH N/A
- AQST 2018
- Fundamental
- Price
- BH $179.50
- AQST $5.08
- Analyst Decision
- BH
- AQST Strong Buy
- Analyst Count
- BH 0
- AQST 7
- Target Price
- BH N/A
- AQST $9.43
- AVG Volume (30 Days)
- BH 1.9K
- AQST 1.5M
- Earning Date
- BH 11-15-2024
- AQST 11-04-2024
- Dividend Yield
- BH N/A
- AQST N/A
- EPS Growth
- BH N/A
- AQST N/A
- EPS
- BH N/A
- AQST N/A
- Revenue
- BH $362,194,000.00
- AQST $58,900,000.00
- Revenue This Year
- BH N/A
- AQST $16.97
- Revenue Next Year
- BH N/A
- AQST N/A
- P/E Ratio
- BH N/A
- AQST N/A
- Revenue Growth
- BH N/A
- AQST 22.56
- 52 Week Low
- BH $137.01
- AQST $1.55
- 52 Week High
- BH $219.00
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- BH 63.77
- AQST 49.36
- Support Level
- BH $170.85
- AQST $4.62
- Resistance Level
- BH $173.00
- AQST $5.80
- Average True Range (ATR)
- BH 3.12
- AQST 0.34
- MACD
- BH 1.02
- AQST -0.06
- Stochastic Oscillator
- BH 83.13
- AQST 38.98
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations, and Maxim. The majority of revenue is derived from the Restaurant Operations segment. The Restaurant Operations segment includes Steak n Shake and Western Sizzlin Restaurant businesses.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.